Phase 1/2 BRUIN study reveals 83% overall response rate in relapsed/refractory Waldenström macroglobulinemia, suggesting effective treatment with pirtobrutinib.
Key Points
Pirtobrutinib achieved a complete response in 1% of relapsed/refractory Waldenström macroglobulinemia patients, showcasing its effectiveness.
Among 80 patients, the overall response rate was 83%, indicating the potential of pirtobrutinib in treating this condition.
Treatment involved pirtobrutinib with a median follow-up of 35 months, providing critical long-term data for efficacy and safety.
Low rates of dose reduction and discontinuation were observed, highlighting the tolerability of pirtobrutinib despite some treatment-related adverse events.